Literature DB >> 9230212

Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer.

C P Strassburg1, M P Manns, R H Tukey.   

Abstract

One of the most important processes controlling cellular detoxification is carried out in the endoplasmic reticulum by glucuronidation, and most likely plays an important role in the defense mechanism against chemical-induced carcinogenesis. The human UDP-glucuronosyltransferase UGT1A locus encodes up to 12 unique transferases that are transcribed through selective exon sharing. Little is known about how this locus is regulated in human tissues. We present evidence that the UGT1A gene products are differentially expressed in normal liver tissue, which is composed of hepatocellular and biliary tissue, as well as in malignant and premalignant tumor tissue. In liver, UGT1A1, UGT1A3, UGT1A4, and UGT1A9 are expressed, and are all significantly down-regulated in malignant hepatocellular carcinoma and its premalignant precursor, hepatic adenoma, but not in benign focal nodular hyperplasia. UGT1A6, which is expressed abundantly in liver, is not significantly regulated in liver tumors. UGT1A10, a newly discovered UGT1A gene product, is expressed only in biliary and not hepatocellular tissue and is also significantly down-regulated in cholangiocellular carcinoma. Differential regulation between normal biliary tissue and tumor is also observed with UGT1A4. These findings implicate the regulation of the UGT1A locus as a putative early event in hepatocarcinogenesis that discriminates between benign and malignant hepatotumorigenesis and indicates that a complex mode of cellular control underlies the regulation of this locus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9230212

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

Review 1.  Autoimmunity in liver diseases.

Authors:  C P Strassburg; P Obermayer-Straub; M P Manns
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Humanized UGT1 Mice, Regulation of UGT1A1, and the Role of the Intestinal Tract in Neonatal Hyperbilirubinemia and Breast Milk-Induced Jaundice.

Authors:  Shujuan Chen; Robert H Tukey
Journal:  Drug Metab Dispos       Date:  2018-08-09       Impact factor: 3.922

Review 3.  Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.

Authors:  Tessa M Bosch; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Inhibition of human UGT2B7 gene expression in transgenic mice by the constitutive androstane receptor.

Authors:  M F Yueh; P L Mellon; R H Tukey
Journal:  Mol Pharmacol       Date:  2011-03-17       Impact factor: 4.436

5.  Developmental aspects of human hepatic drug glucuronidation in young children and adults.

Authors:  C P Strassburg; A Strassburg; S Kneip; A Barut; R H Tukey; B Rodeck; M P Manns
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

6.  Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor.

Authors:  Wen Xie; Mei-Fei Yeuh; Anna Radominska-Pandya; Simrat P S Saini; Yoichi Negishi; Bobbie Sue Bottroff; Geraldine Y Cabrera; Robert H Tukey; Ronald M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

7.  Interaction between oxidative stress sensor Nrf2 and xenobiotic-activated aryl hydrocarbon receptor in the regulation of the human phase II detoxifying UDP-glucuronosyltransferase 1A10.

Authors:  Sandra Kalthoff; Ursula Ehmer; Nicole Freiberg; Michael P Manns; Christian P Strassburg
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

8.  UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal).

Authors:  Paula R Pacheco; Maria J Brilhante; Cristina Ballart; Francesc Sigalat; Helena Polena; Rita Cabral; Claudia C Branco; Luisa Mota-Vieira
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

9.  Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11).

Authors:  Shujuan Chen; Mei-Fei Yueh; Cyril Bigo; Olivier Barbier; Kepeng Wang; Michael Karin; Nghia Nguyen; Robert H Tukey
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

Review 10.  Species differences in drug glucuronidation: Humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humans.

Authors:  Ryoichi Fujiwara; Emiko Yoda; Robert H Tukey
Journal:  Drug Metab Pharmacokinet       Date:  2017-10-07       Impact factor: 3.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.